阿瑞匹坦胶囊图片及介绍

Aprepitant capsule (trade name: Yimei) is a dose-dependent CYP3A4 inhibitor that is clinically administered in combination with other antiemetic drugs. It is suitable for: preventing acute and delayed nausea and vomiting that occur during the initial and repeated treatment of highly emetogenic anti-tumor chemotherapy. Aprepitant has been on the market in the United States since 2004, and its effectiveness and safety have strong scientific research and clinical support. On March 29, 2014, Merck China announced in Beijing that the capsule, a drug it developed to prevent nausea and vomiting caused by chemotherapy, has been approved by the China Food and Drug Administration for marketing in China.

The original drug of aprepitant capsules is developed and produced by Merck in the United States. Merck is headquartered in Kenilworth, New Jersey, United States. Merck has become a leader in the global medical industry and is committed to improving the health of the global public. With prescription drugs, vaccines and biologics and animal health products, it provides innovative medical solutions to more than 140 markets around the world. In 2020, Merck's annual revenue was US$48 billion, and its R&D investment exceeded US$13.5 billion.

Aprepitant capsules, administered in combination with other antiemetic drugs, are indicated for the prevention of acute and delayed nausea and vomiting during initial and repeated treatment with highly emetogenic antineoplastic chemotherapy. Aprepitant is the first NK-1 receptor antagonist, which binds highly selectively to NK-1 receptors in the brain and antagonizes substance P. Substance P is a neurokinin located in the nerves of the central and peripheral nervous systems. It acts through NK-1 receptors and is related to various inflammatory immune responses such as vomiting, depression, pain and asthma. Aprepitant can effectively prevent vomiting, and its antiemetic regimen combined with 5-HT3 receptor antagonists and glucocorticoids has also been recommended by international authoritative guidelines.

Aprepitant capsules are administered as a three-day intervention and include a course of treatment with a corticosteroid and a 5-HT3 antagonist. The recommended dosage of capsules is 125 mg taken orally one hour before chemotherapy on the first day, and 80 mg once daily in the morning on the second and third days.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.